The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and Mitigation Strategy. The proposal would require that certain solid oral dosage forms of immediate-release opioid analgesics commonly prescribed to treat acute pain be made available in fixed-quantity blister packaging for outpatient dispensing. “This could reduce the amount of unused opioid analgesics, thereby reducing opportunities for misuse, abuse, inappropriate access and overdose, and possibly reducing the development of new opioid addiction,” the agency said. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 allows the FDA to require special packaging for opioids and other drugs that pose a risk of abuse or overdose. 

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.
Headline
The AHA yesterday announced support for the Opioid Workforce Act of 2019, bipartisan legislation to reduce the nation’s shortage of opioid treatment providers…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, of which the AHA is a sponsor, held a two-day meeting this week…